You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 302 No. 8, August 26, 2009 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Bacterial Infections
 •Travel Medicine
 •Drug Therapy
 •Drug Therapy, Other
 •Infectious Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Typhoid Fever in the United States, 1999-2006

Michael F. Lynch, MD, MPH; Elizabeth M. Blanton, MPH; Sandra Bulens, MPH; Christina Polyak, MD, MPH; Jazmin Vojdani, MPH; Jennifer Stevenson, MPH, PhD; Felicia Medalla, MD; Ezra Barzilay, MD; Kevin Joyce, BS; Timothy Barrett, PhD; Eric Daniel Mintz, MD, MPH

JAMA. 2009;302(8):859-865.

Context  Typhoid fever in the United States has increasingly been due to infection with antimicrobial-resistant Salmonella ser Typhi. National surveillance for typhoid fever can inform prevention and treatment recommendations.

Objective  To assess trends in infections with antimicrobial-resistant S Typhi.

Design  Cross-sectional, laboratory-based surveillance study.

Setting and Participants  We reviewed data from 1999-2006 for 1902 persons with typhoid fever who had epidemiologic information submitted to the Centers for Disease Control and Prevention (CDC) and 2016 S Typhi isolates sent by participating public health laboratories to the National Antimicrobial Resistance Monitoring System Laboratory at the CDC for antimicrobial susceptibility testing.

Main Outcome Measures  Proportion of S Typhi isolates demonstrating resistance to 14 antimicrobial agents and patient risk factors for antimicrobial-resistant infections.

Results  Patient median age was 22 years (range, <1-90 years); 1295 (73%) were hospitalized and 3 (0.2%) died. Foreign travel within 30 days of illness was reported by 1439 (79%). Only 58 travelers (5%) had received typhoid vaccine. Two hundred seventy-two (13%) of 2016 isolates tested were resistant to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug-resistant S Typhi [MDRST]); 758 (38%) were resistant to nalidixic acid (nalidixic acid–resistant S Typhi [NARST]) and 734 NARST isolates (97%) had decreased susceptibility to ciprofloxacin. The proportion of NARST increased from 19% in 1999 to 54% in 2006. Five ciprofloxacin-resistant isolates were identified. Patients with resistant infections were more likely to report travel to the Indian subcontinent: 85% of patients infected with MDRST and 94% with NARST traveled to the Indian subcontinent, while 44% of those with susceptible infections did (MDRST odds ratio, 7.5; 95% confidence interval, 4.1-13.8; NARST odds ratio, 20.4; 95% confidence interval, 12.4-33.9).

Conclusion  Infection with antimicrobial-resistant S Typhi strains among US patients with typhoid fever is associated with travel to the Indian subcontinent, and an increasing proportion of these infections are due to S Typhi strains with decreased susceptibility to fluoroquinolones.


Author Affiliations: Enteric Diseases Epidemiology Branch (Drs Lynch, Polyak, Stevenson, Medalla, Barzilay, and Mintz and Mss Blanton, Bulens, and Vojdani), Enteric Diseases Laboratory Branch (Mr Joyce and Dr Barrett), Division of Foodborne, Bacterial and Mycotic Diseases, and Office of the Chief Science Officer (Dr Barrett), National Center for Zoonotic Vector-borne and Enteric Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED LETTERS

Typhoid Fever in the United States and Antibiotic Choice
Buddha Basnyat
JAMA. 2010;303(1):34.
EXTRACT | FULL TEXT  

Typhoid Fever in the United States and Antibiotic Choice—Reply
Michael F. Lynch and Eric D. Mintz
JAMA. 2010;303(1):34-35.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Addressing the Global Disease Burden of Typhoid Fever
Zulfiqar A. Bhutta and John Threlfall
JAMA. 2009;302(8):898-899.
EXTRACT | FULL TEXT  

Typhoid Fever
Huan J. Chang, Cassio Lynm, and Richard M. Glass
JAMA. 2009;302(8):914.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Typhoid Fever in the United States and Antibiotic Choice
Basnyat
JAMA 2010;303:34-34.
FULL TEXT  

Addressing the Global Disease Burden of Typhoid Fever
Bhutta and Threlfall
JAMA 2009;302:898-899.
FULL TEXT  

Typhoid Fever in the U.S.
JWatch Infect. Diseases 2009;2009:1-1.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.